title: Prodrugs: a challenge for the drug development.
abstract: It is estimated that about 10% of the drugs approved worldwide can be classified as prodrugs. Prodrugs, which have no or poor biological activity, are chemically modified versions of a pharmacologically active agent, which must undergo transformation in vivo to release the active drug. They are designed in order to improve the physicochemical, biopharmaceutical and/or pharmacokinetic properties of pharmacologically potent compounds. This article describes the basic functional groups that are amenable to prodrug design, and highlights the major applications of the prodrug strategy, including the ability to improve oral absorption and aqueous solubility, increase lipophilicity, enhance active transport, as well as achieve site-selective delivery. Special emphasis is given to the role of the prodrug concept in the design of new anticancer therapies, including antibody-directed enzyme prodrug therapy (ADEPT) and gene-directed enzyme prodrug therapy (GDEPT).
authors.affiliation: Institute of Medical Biology, Polish Academy of Sciences, Lodowa 106, PL 93-232 Łódź, Poland. jolanta.zawilska@umed.lodz.pl
authors.forename: Jolanta B
authors.initials: JB
authors.lastname: Zawilska
authors.forename: Jakub
authors.initials: J
authors.lastname: Wojcieszak
authors.forename: Agnieszka B
authors.initials: AB
authors.lastname: Olejniczak
mesh_terms: D000906:Antibodies / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D001693:Biological Transport, Active; D016503:Drug Delivery Systems; D015195:Drug Design; D004798:Enzymes / Q000378:metabolism; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D011355:Prodrugs / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics
chemical_list: D000906:Antibodies; D000970:Antineoplastic Agents; D004798:Enzymes; D011355:Prodrugs